Clinical Professor Anders Fink-Jensen from the University of Copenhagen presented groundbreaking research demonstrating how GLP-1 receptor agonists can reduce alcohol consumption and related behaviors in rodent and non-human primate models. These findings open the door to promising therapeutic approaches that could address the challenges of AUD, a significant public health issue.

Poul Henning Jensen, DANDRITE Director, praised the collaboration:
“Co-hosting the seminar on the relation of therapeutic metabolic regulation of brain function with Research Director Niels Jessen at SDC was a great opportunity to interact with both the psychiatric and neurological clinicians at AUH, and the preclinical neuroscientists at the Translational Neuropsychiatry Unit."

He adds:
Prof. Anders Fink-Jensen covered brilliantly the topic from mouse and monkey to ongoing clinical efforts. It was exciting to see the broad interest in understanding the effect of GLP-1 agonists on brain functions, which holds promise for future local and national collaborative projects.”

The seminar underscored the importance of translational research, bridging the gap between basic neuroscience and clinical application. With GLP-1 receptor agonists showing potential in both metabolic regulation and psychiatric treatment, the event fostered meaningful discussions about future research collaborations that could transform treatment for AUD and other brain disorders.